Zytiga Pre-chemo Data Impress At ASCO, But Early Trial Termination Could Be An Issue
This article was originally published in The Pink Sheet Daily
Data from a Phase III trial of Johnson & Johnson’s blockbuster prostate cancer drug Zytiga, which was halted for efficacy in March, were released June 2 at ASCO, but at least one expert in the field questions whether the risk to the eventual clinical results was worth it.
You may also be interested in...
J&J’s abiraterone gains FDA clearance for the new claim without statistical significance for its 5-month survival advantage, but Medivation’s Xtandi is waiting in the wings – and its pre-chemo trial, PREVAIL, is likely to show a significant effect.
FDA approval of Zytiga in the pre-chemo setting gives the androgen blocker a second prostate cancer indication and another revenue stream – but a short remaining patent life and a significant competitive threat may mitigate the achievement.
Details from the COU-302 trial of Johnson & Johnson’s Zytiga, stopped early for efficacy in March, were released at the American Society of Clinical Oncology meeting, revealing to Medivation/Astellas insights on how to tweak their ongoing registrational trial for enzalutamide (MDV3100) in the pre-chemo prostate cancer space.